Description
This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same person whose Treg were removed, given back by IV infusion (intravenously) and in combination with low-dose IL-2 in people with Amyotrophic Lateral Sclerosis (ALS). [NCT04055623]
